ENXTPA:IVABiotechs
Does Inventiva (ENXTPA:IVA) Have the Funding Base to Sustain Its Lanifibranor Ambitions?
Recently, Barclays initiated coverage on Inventiva with an Overweight rating, while H.C. Wainwright reiterated its positive stance following a Keystone Obesity Conference presentation on a next-generation conjugate linked to lead candidate lanifibranor and the company’s announcement of a US$172.5 million equity financing to support its NATiV3 Phase 3 trial.
Together, the supportive analyst views, external scientific validation, and fresh funding illustrate how Inventiva is working to advance...